Patient characteristics and management practices in chronic myeloid leukemia in Turkey : reflections from an expert meeting
INTRODUCTION: The therapeutic landscape of chronic myeloid leukemia (CML) has evolved significantly since the introduction of imatinib. The European LeukemiaNet (ELN) recommendations serve as a guide for diagnosis, treatment, and monitorization of CML, but availability and accessibility of diagnostic tools and medications affect their applicability.
AREAS COVERED: This article provides an overview of the current clinical management of CML in Turkey with reference to the key outputs of the online expert meeting held in November 2020. The applicability of the ELN 2020 recommendations for treating CML in clinical practice was also discussed.
EXPERT OPINION: Imatinib is the only reimbursed and the most preferred first-line treatment in CML restricting the upfront use of second-generation tyrosine kinase inhibitors (TKIs), thereby limiting the applicability of treatment-free remission approach in Turkey. The ELN recommendations about using the EUTOS Long-Term Survival (ELTS) score for risk assessment and focusing on patient reported outcomes and quality of life can be enhanced with educational activities. The widespread availability of standardized technical infrastructure for diagnosing and monitoring CML will contribute to better disease management. Establishing a sustainable national database for CML is valuable for observing patient characteristics and disease outcomes as well as the impact of treatment patterns over time.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Expert review of hematology - 15(2022), 2 vom: 21. Feb., Seite 97-106 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Eşkazan, Ahmet Emre [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.04.2022 Date Revised 01.06.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/17474086.2022.2044779 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337164924 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337164924 | ||
| 003 | DE-627 | ||
| 005 | 20231225233805.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/17474086.2022.2044779 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1123.xml |
| 035 | |a (DE-627)NLM337164924 | ||
| 035 | |a (NLM)35184657 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Eşkazan, Ahmet Emre |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Patient characteristics and management practices in chronic myeloid leukemia in Turkey |b reflections from an expert meeting |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.04.2022 | ||
| 500 | |a Date Revised 01.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: The therapeutic landscape of chronic myeloid leukemia (CML) has evolved significantly since the introduction of imatinib. The European LeukemiaNet (ELN) recommendations serve as a guide for diagnosis, treatment, and monitorization of CML, but availability and accessibility of diagnostic tools and medications affect their applicability | ||
| 520 | |a AREAS COVERED: This article provides an overview of the current clinical management of CML in Turkey with reference to the key outputs of the online expert meeting held in November 2020. The applicability of the ELN 2020 recommendations for treating CML in clinical practice was also discussed | ||
| 520 | |a EXPERT OPINION: Imatinib is the only reimbursed and the most preferred first-line treatment in CML restricting the upfront use of second-generation tyrosine kinase inhibitors (TKIs), thereby limiting the applicability of treatment-free remission approach in Turkey. The ELN recommendations about using the EUTOS Long-Term Survival (ELTS) score for risk assessment and focusing on patient reported outcomes and quality of life can be enhanced with educational activities. The widespread availability of standardized technical infrastructure for diagnosing and monitoring CML will contribute to better disease management. Establishing a sustainable national database for CML is valuable for observing patient characteristics and disease outcomes as well as the impact of treatment patterns over time | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CML | |
| 650 | 4 | |a Chronic myeloid leukemia | |
| 650 | 4 | |a TFR | |
| 650 | 4 | |a TKI | |
| 650 | 4 | |a comorbidities | |
| 650 | 4 | |a risk scoring | |
| 650 | 4 | |a treatment-free remission | |
| 650 | 4 | |a tyrosine kinase inhibitor | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Imatinib Mesylate |2 NLM | |
| 650 | 7 | |a 8A1O1M485B |2 NLM | |
| 700 | 1 | |a Ali, Rıdvan |e verfasserin |4 aut | |
| 700 | 1 | |a Alnıgeniş, Ebru |e verfasserin |4 aut | |
| 700 | 1 | |a Ayyıldız, Orhan |e verfasserin |4 aut | |
| 700 | 1 | |a Haznedaroğlu, İbrahim |e verfasserin |4 aut | |
| 700 | 1 | |a Kırkızlar, Onur |e verfasserin |4 aut | |
| 700 | 1 | |a Kurtoğlu, Erdal |e verfasserin |4 aut | |
| 700 | 1 | |a Malhan, Simten |e verfasserin |4 aut | |
| 700 | 1 | |a Öksüz, Ergün |e verfasserin |4 aut | |
| 700 | 1 | |a Polat, Özlem |e verfasserin |4 aut | |
| 700 | 1 | |a Saydam, Güray |e verfasserin |4 aut | |
| 700 | 1 | |a Sönmez, Mehmet |e verfasserin |4 aut | |
| 700 | 1 | |a Toprak, Selami Koçak |e verfasserin |4 aut | |
| 700 | 1 | |a Toptaş, Tayfur |e verfasserin |4 aut | |
| 700 | 1 | |a Turgut, Mehmet |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of hematology |d 2008 |g 15(2022), 2 vom: 21. Feb., Seite 97-106 |w (DE-627)NLM190987367 |x 1747-4094 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2022 |g number:2 |g day:21 |g month:02 |g pages:97-106 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/17474086.2022.2044779 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2022 |e 2 |b 21 |c 02 |h 97-106 | ||